STRATA Skin Sciences, Inc. · OTC:SSKN

STRATA Skin Sciences — Investor Presentation (August 2022)

28 slides from STRATA Skin Sciences's investor presentation, Aug 29, 2022

  1. Slide 1: Driving Value to Dermatology Partners Matching Patients with Clinics

    Investor Presentation December 2020 Investor Presentation August 2022 Driving Value to Dermatology Partners Matching Patients with Clinics

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,”

  3. Slide 3: Company Overview

    3 Company Overview A medical technology company dedicated to developing cutting-edge solutions for the in-office treatment of life-altering skin conditions. PhotoMedex Mela Skin Sciences Global leader in dermatology excimer laser Expanding domestic and international presence in key markets 1000+ XTR

  4. Slide 4: Positioned for Growth Acceleration in the Treatment of Chronic Skin Conditions

    Positioned for Growth Acceleration in the Treatment of Chronic Skin Conditions 4 CEO CFO VP Marketing VP of Professional Relations Head of International Sales Director of Business Operations 3 new Board Members New Leadership Commercial Focus and Execution Acquisitions DTC marketing analytics Direct

  5. Slide 5: Chronic Dermatologic Conditions Treated with XTRAC Excimer Laser

    Chronic Dermatologic Conditions Treated with XTRAC Excimer Laser 5 ECZEMA PSORIASIS VITILIGO PSORIASIS: Autoimmune disease that causes the skin to regenerate faster than normal; characterized by red, itchy scaly patches (65% Mild; 25% Moderate; 10% Severe) ~8 Million patients in the U.S.3 VITILIGO:

  6. Slide 6: XTRAC Treatments by Indication – United States

    XTRAC® Treatments by Indication – United States 6 5% 80% 15% Opportunities exist for expanding use for other approved indications Vitiligo Eczema (Atopic Dermatitis) #1use for XTRAC® lasers domestically Psoriasis treatments remain

  7. Slide 7: XTRAC: Psoriasis

    XTRAC®: Psoriasis 7 After 4 tx After 2 tx Baseline Clinical Protocol – 6.2 treatments to PASI 75 Beam of UVB light applied to the affected area PASI – A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trial

  8. Slide 8: XTRAC: Vitiligo

    XTRAC®: Vitiligo 8 Beam of UVB light applied to the affected area XTRAC®The solution for Vitiligo Results in re-pigmentation UVB light reduces the immune system’s attack on the melanocytes Simple, safe, effective + long-lasting Excimer laser Baseline After 18 tx After 29 tx

  9. Slide 9: Sample Studies from 150+ Clinical Studies

    Multicenter Psoriasis Study7 124 patients were enrolled and 80 completed the protocol. 72% achieved at least 75% clearing in an average of 6.2 treatments. 84% of patients reached improvement of 75% or better after 10 or fewer treatments. 50% of patients reached improvement of 90% or better after 10

  10. Slide 10: Treatment Options Addressing Psoriasis Indication

    Treatment Options Addressing Psoriasis Indication6 10 XTRAC NB-UVB* Topical Steroids Non-biologic Systemics Biologics Approximate Costs ($) Cost competitive 1K-3K 3K-9K 1K -7K 1K 32K-68K Clinical Impact Better clinical outcomes (PASI%75) 92% 71% 75% 48% 50-70% Speed of Onset (in weeks) Very fast rat

  11. Slide 11: XTRAC is the Leader in Targeted 308nm Excimer Laser Therapy

    Best-in-class Excimer TREATMENT XTRAC® is the Leader in Targeted 308nm Excimer Laser Therapy 11 Safe & Effective Treatment 150+ Peer-Reviewed Clinical Studies Economical for Patients and Payors Win-Win for Providers and their Patients

  12. Slide 12: Growing Installed Base Drives Recurring Revenue Model

    Growing Installed Base Drives Recurring Revenue Model 12 Systems FY 19 Systems FY 20 Systems FY 21 Net Installed Base Growth 2019 – 1H 2022 28% growth in installed base over the last 3+ years Actively redeploying under utilized devices Group placements and Ra Medical conversions drive growth +160 -7

  13. Slide 13: A True Partnership – Delivering a Complete Business Solution

    A True Partnership – Delivering a Complete Business Solution 13 Clinical Support Reimbursement Support Call Center Support Field Service Support Consumables and Parts Laser Upgrades Co-pay Assistance DTC Marketing

  14. Slide 14: Key Priority: Driving Commercial Execution

    Key Priority: Driving Commercial Execution 14 Sustain investment in DTC marketing Continue to focus and grow high-volume accounts Drive increased utilization across all indications Increase marketing to drive awareness among derms Historical trends show positive correlation between DTC investment an

  15. Slide 15: Domestic Market: Sales and Service Engine

    Domestic Market: – Sales and Service Engine Overview 4 Regions 30 Sales Territories 2 National Account Managers 15 Field Service Techs In-House Call Center to Qualify Leads Predominant Provider of Excimer Laser Treatments 15 Territories color coded

  16. Slide 16: XTRAC Installed Base – Multiple Growth Drivers

    XTRAC® Installed Base – Multiple Growth Drivers International Current Markets: China, Japan, Saudi Arabia, S. Korea, Israel Insurance covered in most markets Usage per device higher than U.S. market 1,300 devices sold and in service 55 International partner XTRAC® clinics (up from 10 in 2019) 16 1,9

  17. Slide 17: Acquired the U.S. Dermatology Business of Ra Medical Systems

    Acquired the U.S. Dermatology Business of Ra Medical Systems 17 Provides STRATA with the opportunity to market its full business solution to Ra Medical’s existing customer base of 250+ active accounts Positions STRATA as the predominant provider of excimer laser treatments in the U.S. Thru 06/31/202

  18. Slide 18: Theraclear Acquisition

    Theraclear Acquisition 18 Substantially broadens STRATA’s opportunity with expansion potential into the estimated $5.5B acne care market Creates robust pipeline of opportunities to target conditions beyond acne with a unique light treatment approach Reinforces STRATA’s vision to be the premier provi

  19. Slide 19: TheraClearX Acne System

    TheraClear®X Acne System The TheraClearX Acne System is FDA cleared for the treatment of multiple acne forms ● Acne Vulgaris ● Pustular Acne ● Comedonal Acne Dual mechanism of action (MOA) combining negative pressure vacuum with pulsed broadband light delivered through a liquid cooled, handheld deli

  20. Slide 20: Executive Management Team

    Executive Management Team: 100+ yrs. dermatology experience Robert (Bob) J. Moccia, CEO Encore Dermatology, Precision Dermatology, Medicis Pharmaceuticals, Graceway Pharmaceuticals, Bioglan Pharmaceuticals, Stiefel Laboratories, Dermik Laboratories (RPR) Chris Lesovitz, CFO Encore Dermatology, Iroko

  21. Slide 21: Financial Metrics

    Financial Metrics 21 * Unaudited quarterly results 2018 2019 2020 Q1 '21* Q2 '21* Q3 '21* Q4 '21* 2021 Q1’22* Q2’22* Recurring revenue $21,053 $23,713 $17,409 $4,679 $5,452 $5,710 $6,687 $22,528 $5,067 $5,582 Equipment revenue $8,802 $7,873 $5,681 $1,148 $1,930 $2,001 $2,370 $7,449 $1,974 $3,523 Tot

  22. Slide 22: Commercial Drivers in 2022

    Commercial Drivers in 2022 22 Continue DTC advertising campaign with social media XTRAC® Awareness: Co-Op advertising to suitable patients (digital + print) Develop patient advocacy partnerships Broadened commercial strategy to expand use within partner practices Added emphasis on professional relat

  23. Slide 23: STRATA Key Investment Takeaways

    STRATA Key Investment Takeaways 23 Differentiated Treatment providing a Win-Win-Win for Patients + Clinics + Payers Addressing Large and Growing Markets + Positioned for Inorganic Growth Proven Business Model to Expand + Achieve Sustainable Results and Shareholder Returns

  24. Slide 24: Thank You

    Investor Presentation December 2020 Thank You

  25. Slide 25: Appendix

    Investor Presentation December 2020 Appendix

  26. Slide 26: Board of Directors

    Board of Directors William Humphries Chairman of the Board and Governance & Compensation Committee CEO, Isosceles Pharmaceuticals, Inc. former President & Group Chairman Ortho Dermatologics, Merz Pharmaceuticals, Stiefel Pharmaceuticals, Allergan Pharmaceuticals Dr. Uri Geiger CEO Accelmed Inc. CEO

  27. Slide 27: Partner Academic Institutions

    Partner Academic Institutions 27

  28. Slide 28: Footnotes

    Footnotes Company estimates Historical phototherapy utilization. Trend in phototherapy utilization among Medicare beneficiaries by billing code across all providers, 2000 to 2015. HCPCS, Healthcare Common Procedure Coding System; PUVA, psoralen plus ultraviolet A; UVB, ultraviolet B National Eczema

STRATA Skin Sciences — Investor Presentation (August 2022) on 6ix